RESEARCH - Vaccination response to tetanus and pneumococcal vaccines following administration of Orencia

[Guest guest]

Arthritis Res Ther. 2007;9(2):R38.

Vaccination response to tetanus toxoid and 23-valent pneumococcal

vaccines following administration of a single dose of abatacept: a

randomized, open-label, parallel group study in healthy subjects.

Tay L, Leon F, Vratsanos G, R, Corbo M.

Clinical Discovery, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ

08543-4000, USA.

The effect of abatacept, a selective T-cell co-stimulation modulator,

on vaccination has not been previously investigated. In this

open-label, single-dose, randomized, parallel-group, controlled study,

the effect of a single 750 mg infusion of abatacept on the antibody

response to the intramuscular tetanus toxoid vaccine (primarily a

memory response to a T-cell-dependent peptide antigen) and the

intramuscular 23-valent pneumococcal vaccine (a less T-cell-dependent

response to a polysaccharide antigen) was measured in 80 normal

healthy volunteers. Subjects were uniformly randomized to receive one

of four treatments: Group A (control group), subjects received

vaccines on day 1 only; Group B, subjects received vaccines 2 weeks

before abatacept; Group C, subjects received vaccines 2 weeks after

abatacept; and Group D, subjects received vaccines 8 weeks after

abatacept. Anti-tetanus and anti-pneumococcal (Danish serotypes 2, 6B,

8, 9V, 14, 19F and 23F) antibody titers were measured 14 and 28 days

after vaccination. While there were no statistically significant

differences between the dosing groups, geometric mean titers following

tetanus or pneumococcal vaccination were generally lower in subjects

who were vaccinated 2 weeks after receiving abatacept, compared with

control subjects. A positive response (defined as a twofold increase

in antibody titer from baseline) to tetanus vaccination at 28 days was

seen, however, in > or = 60% of subjects across all treatment groups

versus 75% of control subjects. Similarly, over 70% of

abatacept-treated subjects versus all control subjects (100%)

responded to at least three pneumococcal serotypes, and approximately

25-30% of abatacept-treated subjects versus 45% of control subjects

responded to at least six serotypes.

PMID: 17425783

http://www.ncbi.nlm.nih.gov/pubmed/17425783

Not an MD